Philip Grant
Academic Appointments
- Instructor, Medicine - Infectious Diseases
Key Documents
Contact Information
-
Clinical Offices
Positive Care Clinic 3351 El Camino Real Suite 225 Atherton, CA 94027 Tel Work (650) 723-9001 Fax (650) 568-1708
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Infectious Disease
Professional Education
| Fellowship: | Stanford University - Infectious Diseases CA (2008) |
| Board Certification: | Infectious Disease, American Board of Internal Medicine (2008) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2003) |
| Internship: | University of Washington Medical Center, WA USA (2001) |
| Medical Education: | UCSF CA (2000) |
Scientific Focus
Clinical Trials
- Recruiting Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
- Not Recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
- Not Recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
- Not Recruiting Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- Not Recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Publications
- When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Curr HIV/AIDS Rep. 2012; (3): 251-8
- Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS. 2011; (2): 211-20
- Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clin Infect Dis. 2010; (8): 984-5; author reply 987-9
- International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother. 2010; (4): 1520-5
- Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Curr Opin Investig Drugs. 2010; (8): 901-10
- Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010; (6): 2473-9
Help